Accuri Cytometers Inc., an Ann Arbor, Mich.-based developer of cell analysis systems, has raised $4 million in Series D funding. The InvestMichigan! Program (co-managed by Credit Suisse) was joined by return backers Fidelity Biosciences, Flagship Ventures, Baird Venture Partners and Arboretum Ventures.
5 min read · 13 July 2009
Transmex Systems International, a Singapore-based provider of tracking and sensing solutions for the knowledge management and security markets, has raised S$1.2 million (US$817k) in second-round VC funding. Return backers include Sirius Angel Fund Pte Ltd. and Spring Seeds Capital.
5 min read · 13 July 2009
Teraco Data Environments Ltd., a provider of vendor-neutral colocation facilities in South Africa, has raised R50 million (US$6m) in Series B funding. Return backer Treacle Private Equity led the round, and was joined by Guy Willner, co-founder and CEO of IXEurope.
3 min read · 13 July 2009
Keytone Ventures has closed its debut fund with $200 million in capital commitments. The China-focused firm's principals are: Joe Zhou, formerly with KPCB China;Stella Jin, formerly with IDG-Accel China Growth Fund; and Peng Jin, also formerly with IDG-Accel China Growth Fund.
2 min read · 12 July 2009
iPeak Networks, an Ottawa-based networking technology startup, has raised an undisclosed amount of Series A funding led by Miralta Capital.
3 min read · 12 July 2009
Merck & Co. (NYSE: MRK) has bought exclusive rights from Portola Pharmaceuticals, to develop and commercialize an oral blood thinner, used to prevent strokes in patients suffering from atrial fibrillation. The deal includes a $50 million up-front payment, plus up to $420 million in milestone-based earnouts. It comes just months after Portola signed a similar deal with Novartis, for an anti-clotting agent, valued at up to $575 million. Portola has raised around $220 million in VC funding, from firms like Abingworth Management, Advanced Technology Ventures, AllianceBernstein, Alta Partners, Brookside Capital, CIDC Consulting, D.E. Shaw, Frazier Healthcare Ventures, Goldman Sachs, IBT Management Corp., MPM Capital, Prospect Venture Partners, Sutter Hill Ventures, Teachers' Private Capital, T. Rowe Price, Apothecary Capital, Janus Capital and PAC-Link BioVentures.
5 min read · 10 July 2009
Digi International Inc. (Nasdaq: DGII) has acquired MobiApps Holdings, a Herndon, Va.-based developer of machine-to-machine communications solutions. No financial terms were disclosed. MobiApps had raised around $18 million in VC funding, from firms like Intel Capital, Green Dot Capital, UOB Venture Management and 3i Group.
3 min read · 10 July 2009
FiberNet Telecom Group Inc. (Nasdaq: FTGX) said that RCN Corp. has withdrawn a $12.50 per share buyout offer. Consequently, the company will persue an $11.45 per share offer from Zayo Group, a Louisville, Colo.-based regional provider of fiber-based network services. The total deal would be valued at around $86 million. Zayo has raised around $225 million in private equity funding, from firms like Morgan Stanley Alternative Investment Partners, Charlesbank Capital Partners, Battery Ventures, Centennial Ventures, Columbia Capital, M/C Venture Partners and Oak Investment Partners.
2 min read · 10 July 2009
PROfounders Capital has held a first close on its inaugural VC fund. No financial information was disclosed. The London-based firm also announced that it has added Sean Seton-Rogers, formerly an associate with Balderton Capital, as a general partner. Other existing team members include Bebo founder Michael Birch, Lastminute.com founder Brent Hoberman, LongAcre Partners founder Jonathan Goodwin and Oakley Capital founder Peter Dubens.
2 min read · 10 July 2009
Presidio Pharmaceuticals Inc., a San Francisco-based drug company focused on small-molecule compounds to treat HIV-1, HCV and other chronic viral infections, has raised $27 million in additional Series B funding. The round now stands at $53 million. New Leaf Venture Partners was joined on the tranche by return backers Panorama Capital, Baker Brothers Investments, Ventures West Capital, Bay City Capital, Nexus Medical Partners and Sagamore BioVentures.
2 min read · 10 July 2009
